Merav Nir Dotan - 14 Aug 2026 Form 4 Insider Report for IceCure Medical Ltd. (ICCM)

Reporting relationship: VP, Human Resources
Issuer ticker: ICCM
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Aug 2026, 08:16:02 UTC
Prior SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Merav Nir Dotan

Key filing fact

Merav Nir Dotan filed Form 4 for IceCure Medical Ltd. (ICCM) on 17 Aug 2026.

Key facts

This page summarizes Merav Nir Dotan's Form 4 filing for IceCure Medical Ltd. (ICCM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Aug 2026, 08:16.

Change

Previous filing in this sequence was filed on 25 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048789 Primary reporting owner

Dotan Merav Nir

Relationship: VP, Human Resources
Address: 7 HA'ESHEL ST., PO BOX 3163, CAESAREA, ISRAEL
Signature: /s/ Merav Nir Dotan
Signature date: 17 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICCM transaction

Ordinary Shares

Award

Transaction value
Shares: +73,890
Change %: +3244%
Price: $0.000000^*
Shares after: 76,168
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents (i) 73,890 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 17 ordinary shares, (iii) 758 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,080 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 440 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.